{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:45:56Z","timestamp":1782708356461,"version":"3.54.5"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Lower cervical spine origin chordomas are exceedingly uncommon tumors, and treatment may present difficulties in particular areas of the cervical spine owing to its specific anatomic architecture and the interrelationship with the vertebral arteries, cervical nerve roots, and spinal cord. Due to its rarity, the mechanisms underlying tumorigenesis and optimal therapeutic strategies for recurrence remain poorly understood. A 57-year-old Chinese female with large vertebral and paravertebral lesions from C6 to T1 underwent surgically resection on Aug 13, 2018. The pathological diagnosis in the post-operative report was chordoma close to the resection margin. No adjuvant treatment was administered after surgery. The first recurrence occurred three years postoperatively and was associated with a high tumor burden. At that time, paraplegia (lower limb paralysis and involuntary urinary and fecal control disorders) occurred. This patient received apatinib tablets, a vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI), as first-line treatment. Second-line administration of a VEGFR-TKI anlotinib capsules and programmed death-1 (PD-1) inhibitor toripalimab injection; third-line administration of the programmed death-ligand 1 (PD-L1) inhibitor adebrelimab injection, resulted in a progression-free survival 3 of 22 months and an overall survival of 7.5 years. To the best of our knowledge, this represents the first reported case of adebrelimab use in immunotherapy for chordoma.<\/jats:p>","DOI":"10.3389\/fonc.2026.1850680","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:26:05Z","timestamp":1782707165000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Liping","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pathology, Shaoxing People\u2019s Hospital","place":["Shaoxing, Zhejiang, China"]},{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shaoxing People\u2019s Hospital","place":["Shaoxing, Zhejiang, China"]},{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shaoxing People\u2019s Hospital","place":["Shaoxing, Zhejiang, China"]},{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkui","family":"Xiong","sequence":"additional","affiliation":[{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, Zhejiang, China"]},{"name":"Department of Radiation Oncology, Shaoxing Second Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009544","article-title":"B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9256","article-title":"Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab","volume":"7","author":"Fujii","year":"2016","journal-title":"Oncotarget"},{"key":"B3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40478-023-01610-0","article-title":"DNA methylation, combined with RNA sequencing, provide novel insight into molecular classification of chordomas and their microenvironment","volume":"11","author":"Baluszek","year":"2023","journal-title":"Acta Neuropathol Commun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/jss.2018.07.09","article-title":"Chordoma of the mobile spine and sacrum: clinical management and prognosis","volume":"4","author":"D'Amore","year":"2018","journal-title":"J Spine Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.946597","article-title":"Research hotspots and trends of chordoma: a bibliometric analysis","volume":"12","author":"Gao","year":"2022","journal-title":"Front Oncol"},{"key":"B6","article-title":"Sacrococcygeal chordoma: report of a case and review of the literature","volume":"78","author":"Gray","year":"1975","journal-title":"Surgery"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22440.1","article-title":"Recent advances in understanding and managing chordomas: an update","volume":"9","author":"Connors","year":"2020","journal-title":"F1000Research"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0740-x","article-title":"Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers","volume":"17","author":"Stacchiotti","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/a:1008947301735","article-title":"Chordoma: incidence and survival patterns in the United States, 1973-1995","volume":"12","author":"McMaster","year":"2001","journal-title":"Cancer Causes Control CCC"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008138","article-title":"Multimodal profiling of chordoma immunity reveals distinct immune contextures","volume":"12","author":"van Oost","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3576","article-title":"Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma","volume":"6","author":"Feng","year":"2015","journal-title":"Oncotarget"},{"key":"B12","article-title":"Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis","volume":"8","author":"Zou","year":"2016","journal-title":"Am J Trans Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70270","article-title":"Lower cervical chordomas: a case report and differential diagnosis","volume":"8","author":"Muenkaew","year":"2025","journal-title":"Cancer Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103003","article-title":"How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers","volume":"140","author":"Stacchiotti","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3171\/case25241","article-title":"Resection of C2 chordoma after failed ion-beam radiotherapy: illustrative case","volume":"10","author":"Onoki","year":"2025","journal-title":"J Neurosurg Case Lessons"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.17691\/stm2023.15.5.05","article-title":"Radiation therapy for chordomas and chondrosarcomas of the skull base: evaluation of the effectiveness of treatment methods (review)","volume":"15","author":"Lemaeva","year":"2023","journal-title":"Sovremennye Tekhnologii v Meditsine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31898","article-title":"Long-term clinical outcome and quality of life of children, adolescents, and young adults with chordoma or chondrosarcoma treated with pencil beam scanning proton therapy","volume":"72","author":"Vazquez","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105013","article-title":"Proton beam therapy for chordoma: a systematic review and meta-analysis","volume":"217","author":"Dong","year":"2026","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.21037\/cco.2018.08.02","article-title":"Advances of systemic treatment for adult soft-tissue sarcoma","volume":"7","author":"Liu","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1257254","article-title":"The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf213","article-title":"Integrated immune profiling of chordomas reveals spatially organized niches and functional heterogeneity","volume":"28","author":"Arrieta","year":"2025","journal-title":"Neuro-Oncology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17213493","article-title":"Comparative outcomes of brachyury vaccine vs. imatinib in advanced chordoma: a Mayo Clinic experience","volume":"17","author":"Navarro-Garcia de Llano","year":"2025","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","first-page":"189520","DOI":"10.1016\/j.bbcan.2025.189520","article-title":"Targeting the tumor immune microenvironment in chordoma: from mechanistic insights to therapeutic breakthroughs","volume":"1881","author":"Zhang","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2025.109222","article-title":"Systematic review of novel target therapies and clinical trials in chordoma","volume":"259","author":"Zeinali","year":"2025","journal-title":"Clin Neurol Neurosurg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3171\/2018.6.spine18362","article-title":"Current treatment strategy for newly diagnosed chordoma of the mobile spine and sacrum: results of an international survey","volume":"30","author":"Dea","year":"2019","journal-title":"J Neurosurg Spine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104544","article-title":"Retrospective multicentric survival analysis of patients receiving TPEx regimen as first-line treatment of recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"10","author":"Libert","year":"2025","journal-title":"ESMO Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12029-025-01259-z","article-title":"Clinical efficacy and safety of apatinib combined with irinotecan in HER2-negative patients with advanced gastric or gastroesophageal junction adenocarcinoma after first-line treatment failure: a single-arm, single-center retrospective study","volume":"56","author":"Huang","year":"2025","journal-title":"J Gastrointestinal Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12967-018-1421-y","article-title":"Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia","volume":"16","author":"Deng","year":"2018","journal-title":"J Transl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11060-019-03221-z","article-title":"Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma","volume":"144","author":"Morimoto","year":"2019","journal-title":"J Neuro-Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30466-6","article-title":"Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study","volume":"21","author":"Liu","year":"2020","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112482","article-title":"Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma","volume":"200","author":"Li","year":"2020","journal-title":"Eur J Med Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.797407","article-title":"Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients","volume":"12","author":"Xia","year":"2021","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133335","article-title":"The immune microenvironment of chordomas: an immunohistochemical analysis","volume":"13","author":"Dridi","year":"2021","journal-title":"Cancers"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03152-1","article-title":"Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas","volume":"71","author":"Duan","year":"2022","journal-title":"Cancer Immunology Immunotherapy CII"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70033","article-title":"Mutational analysis of primary and advanced chordoma tissue using next-generation sequencing","volume":"131","author":"Chan","year":"2025","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyy274","article-title":"Clinical impact of the immune microenvironment in spinal chordoma: immunoscore as an independent favorable prognostic factor","volume":"84","author":"Zou","year":"2019","journal-title":"Neurosurgery"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2080-1","article-title":"Clinicopathologic implications of CD8(+)\/Foxp3(+) ratio and miR-574-3p\/PD-L1 axis in spinal chordoma patients","volume":"67","author":"Zou","year":"2018","journal-title":"Cancer Immunology Immunotherapy CII"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-0876","article-title":"The landscape of alterations from 1407 ultra-rare sarcomas from the AACR GENIE database: clinical implications","volume":"29","author":"Denu","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2024.1375567","article-title":"Role of immunotherapy in treatment refractory chordomas: review of current evidence","volume":"11","author":"Alexander","year":"2024","journal-title":"Front Surg"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092711","article-title":"Chordoma genetic aberrations and targeted therapies panorama: a systematic literature review","volume":"13","author":"Agosti","year":"2024","journal-title":"J Clin Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000431","article-title":"Immune checkpoint inhibitors have clinical activity in patients with recurrent chordoma","volume":"45","author":"Bishop","year":"2022","journal-title":"J\u00a0Immunotherapy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/s1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSe Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41467-024-44875-2","article-title":"Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial","volume":"15","author":"Cho","year":"2024","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2303383","article-title":"Atezolizumab for advanced alveolar soft part sarcoma","volume":"389","author":"Chen","year":"2023","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102408","article-title":"Immunotherapy for chordoma and chondrosarcoma: current evidence","volume":"13","author":"Traylor","year":"2021","journal-title":"Cancers"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.01.028","article-title":"Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent Malignancies in a phase I study","volume":"130","author":"Yang","year":"2020","journal-title":"Eur J Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-025-02281-0","article-title":"Multicenter phase 1\/2 study of onatasertib, a dual TORC1\/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors","volume":"10","author":"Shu","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001088","article-title":"Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study","volume":"32","author":"Liu","year":"2021","journal-title":"Anti-Cancer Drugs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"29209","DOI":"10.1038\/s41598-025-14759-6","article-title":"Efficacy and safety of anlotinib monotherapy for advanced hepatocellular carcinoma and clinical role of alpha-fetoprotein","volume":"15","author":"Chang","year":"2025","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4286","article-title":"Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: a retrospective multiple institution study","volume":"10","author":"Liu","year":"2021","journal-title":"Cancer Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-15412-1","article-title":"Efficacy and safety comparison of small molecule anti-angiogenic drugs in the treatment of bone and soft tissue sarcomas: a network meta-analysis","volume":"26","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf337","article-title":"Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis","volume":"30","author":"Dias","year":"2025","journal-title":"Oncologist"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14027","article-title":"Autocrine VEGF signalling on M2 macrophages regulates PD-L1 expression for immunomodulation of T cells","volume":"23","author":"Lai","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41392-025-02278-9","article-title":"Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab","volume":"10","author":"Toulmonde","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.12.032","article-title":"Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3","volume":"495","author":"Zheng","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0725","article-title":"Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice","volume":"16","author":"Duan","year":"2020","journal-title":"Future Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8247","article-title":"Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors","volume":"47","author":"Ishikura","year":"2022","journal-title":"Oncol Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.02.017","article-title":"Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME","volume":"58","author":"Benmebarek","year":"2025","journal-title":"Immunity"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-089286","article-title":"Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial","volume":"15","author":"Liu","year":"2025","journal-title":"BMJ Open"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s500470","article-title":"Adebrelimab in small cell lung cancer: from current advances to emerging combination strategy and challenge","volume":"19","author":"Yang","year":"2025","journal-title":"Biologics: Targets Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1185577","article-title":"The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1850680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:26:06Z","timestamp":1782707166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1850680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":67,"alternative-id":["10.3389\/fonc.2026.1850680"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1850680","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1850680"}}